Acceleron: Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:ACTIRiib antagonists
Discover how Acceleron Pharma's patent for treating spinal muscular atrophy with ALK4:ActRIIB antagonists aims to increase muscle mass, strength, and bone density in patients.
Read full article »
Acceleron is a Massachusetts-based biopharmaceutical company that develops and commercializes therapies for the treatment of pulmonary and hematologic diseases.
Read more